<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03435380</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00088926</org_study_id>
    <secondary_id>R01CA134722</secondary_id>
    <nct_id>NCT03435380</nct_id>
  </id_info>
  <brief_title>Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer</brief_title>
  <official_title>EMPOWER-II: Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the impact of maximizing patient and
      primary care provider (PCP) activation on breast cancer surveillance rates among women
      previously treated with chest radiotherapy (RT) for a childhood cancer. This is a 12-month,
      3-arm randomized controlled trial using a smartphone intervention with data being collected
      at baseline and 12-months through patient and provider surveys and medical record review.
      Eligible women treated for a childhood cancer with chest RT will be randomly sampled from the
      Childhood Cancer Survivor Study (CCSS) and randomly selected to one of three groups: control,
      patient activation (PA) using a smartphone-based intervention, or patient activation +
      primary care provider activation (PA+PCP) which will include physician materials about breast
      cancer risk in this population along with guidelines for breast cancer surveillance.
      Participants in all groups will receive mailed targeted print materials as an educational
      resource about their previous chest radiation and breast cancer screening recommendations.
      The primary outcome is a medical record confirmed breast MRI and mammogram with the goal of
      increasing the rate of women completing the national guideline-based recommended combination
      of breast MRI and mammogram. This study will test the hypothesis that women in the PA and
      PA+PCP groups will have significantly higher rates of breast cancer surveillance (breast MRI
      and mammogram) than women in the control group. In addition, the hypothesis that women in the
      PA+PCP group will have significantly higher rates of breast cancer surveillance than women in
      the PA group will also be tested.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned, in a ratio of 1:1:1, to one of the three groups: control, patient activation (PA), or patient activation + primary care provider activation (PA+PCP). Participants will remain in the group they are randomized to with no crossover throughout the study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of women who completed a breast MRI and mammogram</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Patient Activation Measure (PAM) - questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Measures patient activation and includes: believing one has an active role to play, having the confidence and knowledge to take action, taking action, and staying the course under stress.</description>
  </other_outcome>
  <other_outcome>
    <measure>Breast Cancer Surveillance Practices - Knowledge of Recommendations (questionnaire)</measure>
    <time_frame>12 months</time_frame>
    <description>The Breast Cancer Surveillance Practices instrument (questionnaire) was developed as part of an effort supported by NCI funding (R21CA106972) and published in JAMA (Oeffinger KC, et al. JAMA, 301:404-414, 2009). The section regarding knowledge of the recommendations was then adapted for the EMPOWER-I Study, supported by NCI R01134722, and includes 3 items to determine if participants have (1) heard of mammography for breast cancer screening (yes, no, not sure), at what age women like the participant should begin getting a mammogram, and how frequently (multiple time frames).</description>
  </other_outcome>
  <other_outcome>
    <measure>Barrier scales (questionnaire)</measure>
    <time_frame>12 months</time_frame>
    <description>Elicits a rank order of the most relevant and important barriers of breast MRI and those associated with mammogram, for those women who did not obtain the recommended screening. The barriers are presented as a list of 13 statements in which there are 5 ranges of measure provided for each statement. The scale ranges include &quot;Not at all,&quot; &quot;A little bit,&quot; &quot;Moderately,&quot; &quot;Quite a bit,&quot; and &quot;Extremely.&quot; The value/response of &quot;Not at all&quot; is considered to be the better outcome, whereas the value/response of &quot;Extremely&quot; is considered to be the worst outcome for the barrier scale. The scale is not combined to compute a total score, since responses are scored for each statement individually.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pros and Cons of Mammography and Breast MRI (questionnaire)</measure>
    <time_frame>12 months</time_frame>
    <description>The Pros and Cons of mammography is a 13-item instrument developed by Rakowski et al (Prev Med 1997). It was used in our Breast Cancer Surveillance Practices instrument (Oeffinger KC, et al. JAMA, 2009). The pros and cons scores (5-point Likert items) are converted to T-scores and then presented as a summary Decisional Balance. For EMPOWER-I Study, we adapted this instrument to also assess a woman's perspective on the pros and cons of breast MRI. This resulted in a 7-item instrument that is analyzed similar to the Pros and Cons of Mammography and presented as a Decisional Balance.</description>
  </other_outcome>
  <other_outcome>
    <measure>Family history of breast cancer (questionnaire)</measure>
    <time_frame>12 months</time_frame>
    <description>This one-item question asks participants whether their mother, sister(s), or daughter(s) have been diagnosed with breast cancer.</description>
  </other_outcome>
  <other_outcome>
    <measure>Perception of breast cancer risk (questionnaire)</measure>
    <time_frame>12 months</time_frame>
    <description>This item was developed for the aforementioned Breast Cancer Surveillance Practices instrument and is a one-time question with asking women how they estimate their risk of breast cancer (with five responses: much more than the average woman, more than the average woman, same as the average woman, less than the average woman, much less than the average woman).</description>
  </other_outcome>
  <other_outcome>
    <measure>Communication with PCP (questionnaire)</measure>
    <time_frame>12 months</time_frame>
    <description>Developed for the EMPOWER-I study, the questionnaire asks participants at the end of the study whether they saw a health care provider during the 12-month study period, whether they discussed breast cancer screening with a provider, and whether the provider responded to the information (5-point Likert). Each of these items will be analyzed separately.</description>
  </other_outcome>
  <other_outcome>
    <measure>Affect</measure>
    <time_frame>12 months</time_frame>
    <description>Will be measured using the adapted and shortened version of the Positive Affect Negative Affect Scale (PANAS). We will focus on emotions related to managing health.</description>
  </other_outcome>
  <other_outcome>
    <measure>Future breast screening intentions</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the Stage of Adoption (Change) for breast cancer surveillance, participants will be asked when they plan to have their next mammogram and/or breast MRI (following the completion of the study).</description>
  </other_outcome>
  <other_outcome>
    <measure>Self-Efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>Measures confidence in discussing breast surveillance with the primary care physician and obtaining the recommended screening using items developed by Champion and colleagues.</description>
  </other_outcome>
  <other_outcome>
    <measure>Primary care provider demographics</measure>
    <time_frame>Baseline</time_frame>
    <description>Age, gender, years in practice, and practice setting.</description>
  </other_outcome>
  <other_outcome>
    <measure>Primary Care Provider Experience</measure>
    <time_frame>12 months</time_frame>
    <description>Most PCPs have taken care of only a few childhood cancer survivors. To ascertain their past experience with caring for this population, we ask PCPs how many childhood cancer survivors they have in their practice panel (0, 1-2, 3-5, &gt;5).</description>
  </other_outcome>
  <other_outcome>
    <measure>Primary care provider comfort level</measure>
    <time_frame>12 months</time_frame>
    <description>Comfort level with caring for adult survivors of childhood cancer (Likert scale)and familiarity with available guidelines (Likert scale).</description>
  </other_outcome>
  <other_outcome>
    <measure>Primary care provider knowledge</measure>
    <time_frame>12 months</time_frame>
    <description>Using a hypothetical vignette of a 29-year old female patient treated for Hodgkin lymphoma with chemotherapy and chest RT, questions will be asked about screening for thyroid dysfunction, breast cancer, and cardiac dysfunction.</description>
  </other_outcome>
  <other_outcome>
    <measure>Economic Measurements</measure>
    <time_frame>12 months</time_frame>
    <description>Replication costs of the intervention and health services from the intervention per participant.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">291</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Early Detection of Cancer</condition>
  <arm_group>
    <arm_group_label>Control (C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Targeted mailed educational materials (C).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient activation (PA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C + patient activation (PA) consisting of (1) smartphone app with HIPAA compliant survivorship care plan that can be viewed, printed, or emailed to their primary care provider; and (2) two-way (interactive) tailored text messages with links to video vignettes discussing the primary barriers to breast MRI and mammography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient activation + primary care provider activation (PA+PCP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>C + PA + PCP activation (PA+PCP) with physician materials about breast cancer risk in this population along with national and international guidelines for breast cancer surveillance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Patient activation</intervention_name>
    <description>Smartphone-based materials including text messages and supplemental short videos focusing on how to find a primary care doctor, the importance of medical screening, and how to talk to a doctor about medical screening. Guidelines for monitoring and maintaining health, such as a survivorship care plan, will also be included in the smartphone-based materials.</description>
    <arm_group_label>Patient activation (PA)</arm_group_label>
    <arm_group_label>Patient activation + primary care provider activation (PA+PCP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Primary care physician activation</intervention_name>
    <description>Mailed educational print materials sent to the participants' primary care doctors about health risks and recommendations for medical screening for adult women who were treated for a childhood cancer with chest radiation.</description>
    <arm_group_label>Patient activation + primary care provider activation (PA+PCP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Mailed educational materials.</description>
    <arm_group_label>Control (C)</arm_group_label>
    <arm_group_label>Patient activation (PA)</arm_group_label>
    <arm_group_label>Patient activation + primary care provider activation (PA+PCP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eligible participants will include women who:

          -  Were diagnosed with a childhood cancer prior to the age of 21 years;

          -  Were treated with â‰¥ 10 Gy of chest RT (recent revision with a lower dose threshold);1

          -  Do not have a history of breast cancer;

          -  Have not had both a breast MRI and mammogram in the previous 24 months;

          -  Do not have a contraindication to MRI (i.e., pacemaker);

          -  Are 25 years of age or older at time of enrollment;

          -  Have an interval from their chest RT to the time of enrollment of at least 8 years;

          -  Have a smartphone;

          -  Are English-speaking.

        Participants will be selected from women in the Childhood cancer Survivor Study (CCSS)
        cohort.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin C Oeffinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer S Ford, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin C Oeffinger, MD</last_name>
    <phone>919-668-2122</phone>
    <email>kevin.oeffinger@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer S Ford, PhD</last_name>
    <phone>646-888-0042</phone>
    <email>fordj@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer S Ford, PhD</last_name>
      <phone>646-888-0042</phone>
      <email>fordj@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kevin C Oeffinger, MD</last_name>
      <phone>919-668-2122</phone>
      <email>kevin.oeffinger@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gregory T Armstrong, MD, MSCE</last_name>
      <phone>901-595-5892</phone>
      <email>greg.armstrong@stjude.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer Survivors</keyword>
  <keyword>Smartphone</keyword>
  <keyword>Mobile Applications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Participants will be recruited from an established cohort (Childhood Cancer Survivor Study), and therefore individual participant data will not be available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

